MA_Thrombin = measure of maximum thrombin-induced platelet-fibrin clot strength; MA_Fibrin = contribution of fibrin to clot strength; MA_ADP or _AA = represents clot strength after adenosine diphosphate (ADP) or arachidonic acid (AA) stimulation.

(A) Graph demonstrating percentage of patients with and without ischemic events displaying high on-treatment platelet reactivity (HPR) as measured by 5 µmol/l adenosine diphosphate (ADP)-induced light transmittance aggregometry. Dashed line indicates cut point for HPR. (B) Graph demonstrating percentage of patients with and without ischemic events displaying HPR as measured by 2-µmol/l ADP-induced thrombelastography. Dashed line indicates cut point for HPR.

ADP = adenosine diphosphate; LTA = light transmittance aggregometry; TEG = thrombelastograph.

Graph demonstrating cumulative event occurrence over 365 days.

Combined receiver-operating characteristic curve for 5-µmol/l ADP-induced LTA and 2-µmol/l ADP-induced TEG at baseline. An area of 0.862 and an area of 0.881 were observed below the curves of LTA and TEG, respectively, with p = 0.0001 for both areas. AUC = area under the curve; other abbreviations as in Figure 3.

(A) Graph demonstrating mean 5 µmol/l ADP-induced platelet aggregation with and without eptifibatide measured by LTA at baseline, 3 h and 18 to 24 h after percutaneous coronary intervention (PCI). *p < 0.0001 for the change in platelet aggregation in patients receiving eptifibatide versus no eptifibatide. p = 0.0004 for platelet aggregation 3 h after PCI in patients receiving eptifibatide versus baseline. (B) Graph demonstrating mean 2 µmol/l ADP-induced platelet aggregation with and without eptifibatide measured by TEG at baseline, 3 h and 18 to 24 h after PCI. *p < 0.0001 for change in platelet aggregation in patients receiving eptifibatide versus no eptifibatide. Abbreviations as in Figure 3.